Abstract:
The breast cancer (BC) targeting doxorubicin (DOX) liposome drug delivery system CSB1-Lipo-DOX-miR101 with the inhibition for multidrug resistance (MDR) was constructed through thin film ultrasonic dispersion technology and ammonium sulfate active drug loading technology. MTT, wound healing, Transwell, DAPI staining, scanning electron microscopy were used to explore drug efficacy and cell behavior changes. The potential target genes of miRNA101 and BC malignancy relevant genes, as well as the possible anti-MDR mechanism were verified and analyzed by Western blot assay combing data base online assay. The results indicated that CSB1-Lipo-DOX-miR101 targets BC cells accurately, and kills BC cells MCF-7 efficiently, especially DOX resistant BC cells MCF-7/ADR. It showed that the drug delivery can inhibit the formation of MDR, improve therapeutic effect of DOX on BC with reducing toxic side effects, and reduce the recurrence rate of BC. The mechanism of the drug formulation for BC therapy and MDR inhibition may be employed by inhibiting the expression of the ABCC5, EZH2, APEX1, ITGB1, Snail1, MMP2 genes.
